rhIL-15 + mogamulizumab

rhIL-15 + mogamulizumab is an investigational combination immunotherapy developed by the National Cancer Institute (NCI) for the treatment of relapsed or refractory T-cell malignancies, including adult T-cell leukemia/lymphoma (ATLL), mycosis fungoides (MF), and Sezary syndrome (SS). The regimen consists of recombinant human interleukin-15 (rhIL-15), a cytokine that promotes the activation and proliferation of natural killer (NK) cells and CD8+ T cells, and mogamulizumab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 4 (CCR4). The combination is designed to leverage rhIL-15's ability to expand the effector cell population required for mogamulizumab-mediated antibody-dependent cellular cytotoxicity (ADCC) against CCR4-expressing tumor cells. However, a Phase 1 clinical trial (NCT04185220) revealed an unfavorable safety profile, with significant toxicities such as acute kidney injury, rash, and infections, despite evidence of NK cell activation and regulatory T-cell depletion.

Brand names

Poteligeo

Other names

recombinant human interleukin-15 + mogamulizumabIL-15 + mogamulizumabrhIL-15 and mogamulizumabrhIL15 and mogamulizumabrhIL 15 and mogamulizumab